GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (FRA:366) » Definitions » Current Deferred Revenue

Entero Therapeutics (FRA:366) Current Deferred Revenue : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entero Therapeutics Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Entero Therapeutics's current deferred revenue for the quarter that ended in Mar. 2024 was €0.00 Mil.

Entero Therapeutics Current Deferred Revenue Historical Data

The historical data trend for Entero Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entero Therapeutics Current Deferred Revenue Chart

Entero Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Entero Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Entero Therapeutics Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Entero Therapeutics's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Entero Therapeutics (FRA:366) Business Description

Traded in Other Exchanges
Address
777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431
First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Entero Therapeutics (FRA:366) Headlines

No Headlines